Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;27(3):e26230.
doi: 10.1002/jia2.26230.

Reasons for disengagement from antiretroviral care in the era of "Treat All" in low- or middle-income countries: a systematic review

Affiliations

Reasons for disengagement from antiretroviral care in the era of "Treat All" in low- or middle-income countries: a systematic review

Rachael M Burke et al. J Int AIDS Soc. 2024 Mar.

Abstract

Introduction: Disengagement from antiretroviral therapy (ART) care is an important reason why people living with HIV do not achieve viral load suppression become unwell.

Methods: We searched two databases and conference abstracts from January 2015 to December 2022 for studies which reported reasons for disengagement from ART care. We included quantitative (mainly surveys) and qualitative (in-depth interviews or focus groups) studies conducted after "treat all" or "Option B+" policy adoption. We used an inductive approach to categorize reasons: we report how often reasons were reported in studies and developed a conceptual framework for reasons.

Results: We identified 21 studies which reported reasons for disengaging from ART care in the "Treat All" era, mostly in African countries: six studies in the general population of persons living with HIV, nine in pregnant or postpartum women and six in selected populations (one each in people who use drugs, isolated indigenous communities, men, women, adolescents and men who have sex with men). Reasons reported were: side effects or other antiretroviral tablet issues (15 studies); lack of perceived benefit of ART (13 studies); psychological, mental health or drug use (13 studies); concerns about stigma or confidentiality (14 studies); lack of social or family support (12 studies); socio-economic reasons (16 studies); health facility-related reasons (11 studies); and acute proximal events such as unexpected mobility (12 studies). The most common reasons for disengagement were unexpected events, socio-economic reasons, ART side effects or lack of perceived benefit of ART. Conceptually, studies described underlying vulnerability factors (individual, interpersonal, structural and healthcare) but that often unexpected proximal events (e.g. unanticipated mobility) acted as the trigger for disengagement to occur.

Discussion: People disengage from ART care for individual, interpersonal, structural and healthcare reasons, and these reasons overlap and interact with each other. While HIV programmes cannot predict and address all events that may lead to disengagement, an approach that recognizes that such shocks will happen could help.

Conclusions: Health services should focus on ways to encourage clients to engage with care by making ART services welcoming, person-centred and more flexible alongside offering adherence interventions, such as counselling and peer support.

Keywords: antiretroviral; care cascade; disengagement; loss to care; re-engagement; reasons.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests.

Figures

Figure 1
Figure 1
Study selection.
Figure 2
Figure 2
Conceptual framework for reasons for disengagement.
Figure 3
Figure 3
Aggregated reasons for disengagement reported by each study. GBV, gender‐based violence. Figure shows reasons, inductively grouped (right‐hand column). Shaded boxes indicate the reason was reported by the study. Where reported, the frequency of respondents mentioning the reason is indicated as a %. Where no % or other text is reported, the paper did not report a frequency of this reason.

References

    1. WHO . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach—Second edition. 2016. - PubMed
    1. Frescura L, Godfrey‐Faussett P, Feizzadeh A A, El‐Sadr W, Syarif O, Ghys PD. Achieving the 95 95 95 targets for all: a pathway to ending AIDS. PLoS One. 2022;17:e0272405. - PMC - PubMed
    1. Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low‐level HIV viraemia: a systematic review. Lancet. 2023;402:464–471. - PMC - PubMed
    1. Johnson LF, Meyer‐Rath G, Dorrington RE, Puren A, Seathlodi T, Zuma K, et al. The effect of HIV programs in South Africa on national HIV incidence trends, 2000–2019. J Acquir Immune Defic Syndr. 2022;90:115–123. - PubMed
    1. Haas AD, Zaniewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, et al. Retention and mortality on antiretroviral therapy in sub‐Saharan Africa: collaborative analyses of HIV treatment programmes. J Int AIDS Soc. 2018;21:e25084. - PMC - PubMed

Publication types

Substances